Resources On Demand

Frontage provides integrated solutions to our clients: Formulation, Product Development, Analytical Testing, from preclinical to clinical drug development, including commercial products.

Frontage’s Bioanalytical Team is highly experienced in developing, qualifying, and validating biomarker assays for Alzheimer's Disease. Our biomarker assay services provide accurate, reliable information for our partners.

Method development, qualification and validation are at the core of our service portfolio. From product characterization to first-in-human to later stages of your drug development/approval cycle, we can support assay development and technology transfer, as well as method qualification and validation for GMP release and long-term stability studies of your drug substances and drug products.

Frontage offers extensive experience and advanced technology in biomarker assay development, validation, and testing, adhering to CAP, CLIA, GLP, and GCLP standards.

Frontage’s CMC portfolio of services spans pre-formulation, drug product formulation development, analytical method development and validation, GLP batches, GMP clinical trial materials (manufacturing, labeling, packaging, and distribution), scale up, pilot and pivotal/registration batches, and commercial manufacturing (to be ready Q3 2024).

Our formulation development experience and capabilities cover a wide range of dosage forms for IND, NDA, ANDA and 505(b)(2) filings.

Frontage Global Drug Discovery Services (GDDS) offers a complete line of chemistry services. Our hit and lead generation (Hit-to-Lead), lead optimization, process chemistry and manufacturing, and customer synthesis enables speedy advancement of compounds from labs to clinics.

Frontage Global Drug Discovery Services (GDDS) offers a comprehensive compound screening platform with a wide range of enzymatic and cell-based assays. Our experienced team of scientists routinely develop and validate new screening assays to support compound selection and advancement. We believe in a customer centric approach, providing real-time communication and reliable consultation to Sponsors.

Frontage Global Drug Discovery Services (GDDS) offers a wide range of in vitro and in vivo pharmacological models, such as oncology, metabolic diseases and inflammation. We believe in a customer-centric approach providing real-time communication and reliable consultations to Sponsors.

Frontage Global Drug Discovery Services (GDDS) offers a full spectrum of in vitro ADME assays for small molecule drug discovery and preclinical development. Our strong focus on lab operations, automation, and project management enables efficient delivery and unparalleled quality. We believe in a customer-centric approach providing real-time communication and reliable consultations to Sponsors.

Frontage staff are dedicated to providing customized laboratory and computational workflows that enable cost-effective and rapid production of informative data sets, leading to advances in biomarker discovery, drug discovery, and basic medical research for its clients.

Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."

The purpose of this study was to develop a better model to improve the quality of ddPCR assay validation, involving how to improve the reliability of accuracy, precision, and sensitivity.

This study is aimed at developing a Nanoemulsion formulation of a poorly water-soluble and thermally, oxidatively, and photolytically unstable active pharmaceutical ingredient (API) for ophthalmic application, specifically for the reduction of intraocular pressure (IOP) and to provide neuroprotection.

In this study, we evaluate the method to identify and quantify leachables using an enhanced HPLC-UV method.

Frontage is a global CRO advancing drug discovery and development with a comprehensive portfolio of genomics services. We deliver accurate and in-depth analyses to move compounds through early discovery and preclinical studies and for translational and clinical programs.

This discussion focuses on the challenges of global drug development and the long-term implications of COVID-19.

Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion, metastasis, disease progression and mortality, thus serving as a novel cancer biomarker. In this paper, we develop and validate an LC-MS/MS method for the quantification of fascin proteins in human serum.

Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.